Physical and Chemical Stability of Palonosetron Hydrochloride with Topotecan Hydrochloride and Irinotecan Hydrochloride during Simulated Y-Site Administration
Author(s): Trissel Lawrence A, Xu Quanyun A
Issue: May/Jun 2005 - Veterinary Compounding
View All Articles in Issue
Page(s): 238-241
Download in electronic PDF format for $65
Abstract: The objective of this study was to evaluate the physical and chemical stability of undiluted palonosetron hydrochloride 50 µg/mL in combination with topotecan hydrochloride 0.1 mg/mL or irinotecan hydrochloride 1 mg/mL in 5% dextrose injection during simulated Y-site administration. Triplicate test samples were prepared by admixing 5 mL of palonosetron hydrochloride with 5 mL of the topotecan hydrochloride or irinotecan hydrochloride admixture. Physical stability was assessed by using a multistep evaluation procedure that included both turbidimetric and particulate measurement as well as visual inspection. Chemical stability was assessed by using stability-indicating high-performance liquid chromatographic analytical techniques to determine drug concentrations. Evaluations were performed initially upon mixing and again 1 and 4 hours after mixing. The palonosetron hydrochloride-topotecan hydrochloride samples were clear and pale yellow when viewed in normal fluorescent room light. When viewed with a Tyndall beam, the samples had a slight haziness. The palonosetron hydrochloride-irinotecan hydrochloride samples were clear and colorless when viewed in normal fluorescent room light and with a Tyndall beam. Measured turbidities remained unchanged; particulate contents were low and changed little. High-performance liquid chromatographic analysis found that palonosetron hydrochloride, topotecan hydrochloride, and irinotecan hydrochloride remained stable throughout the 4- hour test. Little drug loss was observed. Palonosetron hydrochloride is physically compatible and chemically stable with topotecan hydrochloride and with irinotecan hydrochloride during Y-site administration.
Related Keywords: Lawrence A. Trissel, BS, RPh, FASHP, Quanyan A. Xu, PhD, palonosetron hydrochloride, 5-HT3 receptor antagonist, topotecan hydrochloride, irinotecan hydrochloride, cancer chemotherapy, antiemetic, emesis, nausea, vomiting, stability
Related Categories: CANCER AND AIDS, GASTROENTEROLOGY, PEER-REVIEWED, STABILITIES, COMPATIBILITIES